跳至主要内容

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics


Nov. 18-21, 2014
Centre de Convencions Internacional Barcelona (CCIB)
Barcelona, Spain

Late Registration Deadline: Friday, Nov. 14, 2014

Symposium Co-Chairpersons
Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France (EORTC)
Lee J. Helman, National Cancer Institute, Bethesda, Md., USA (NCI)
Jeffrey A. Engelman, Massachusetts General Hospital, Boston, Mass., USA (AACR)
Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2014 Symposium will bring together over 2,000 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection and the impact of new discoveries in molecular biology. During the last few years, numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer. Further clinical progress in cancer treatment will be accomplished mainly through the conduct of translational research projects, efficient new drug development, and the execution of large, prospective, randomised, multicenter cancer clinical trials. This requires a joint and global approach, and early and optimal exchange of information. For these reasons, the symposium has been organized to ensure the maximum amount of interaction and discussion through an exciting range of plenary sessions and lively workshops.
The symposium presents a unique opportunity to meet with academics and scientists in the field of drug discovery and targets in cancer all under one roof. Molecular Targets and Cancer Therapeutics 2014 will build on the success of the previous symposium which was widely praised for the quality of its program and inspirational contributions. This symposium will provide participants with additional educational opportunities as well as an excellent platform for networking. Make plans to join us at this unique platform in Barcelona and strengthen your links in the world of drug development, target selection, and molecular biology.
标签：

评论

发表评论

此博客中的热门博文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites   On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services
发表评论
阅读全文

In Vitro Enzyme Activity Assay

  Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+  in vitro  enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...
发表评论
阅读全文

Pharmacokinetics Services

Pharmacokinetics Services Our pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai government. Preclinical Pharmacokinetics Method development and validation (GLP,Non-GLP) Bioanalysis Pharmacokinetics (Tumor bearing rodents, Bioavailability, Crossover studies, Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB penetration ) Stability in vehicles and plasma Drug interaction studies In vitro metabolic stability CYP 450 inhibition Plasma protein binding studies Distribution studies Excretion studies Prediction an...
发表评论
阅读全文